Continued Growth in Centers Using Apligraf; Over 670 Medical Centers Have Ordered Apligraf.CANTON, Mass.--(BW HealthWire)--June 3, 1999-- Organogenesis organogenesis /or·ga·no·gen·e·sis/ (or?gah-no-jen´e-sis) the origin and development of organs.organogenet´ic or·gan·o·gen·e·sis n. The formation and development of the organs of living things. Inc. (AMEX AMEX See: American Stock Exchange :ORG) today announced the number of US medical centers that have ordered and re-ordered Apligraf(R) and May commercial unit sales unit sales Sales measured in terms of physical units rather than dollars. Unit sales data are often used by financial analysts when evaluating the health of a company. for the product. The number of centers that have ordered Apligraf increased to 674 in May from 603 in April. The number of centers re-ordering the product increased to 369 in May from 321 in April. US commercial unit sales were 552 for May. Apligraf is marketed by Novartis Pharmaceuticals Corporation. -0-
# Sites Ordering Apligraf(A) # Sites Re-Ordering
Month Apligraf(B)
June 1998 8 2
July 1998 38 9
Aug. 1998 80 24
Sept. 1998 135 56
Oct. 1998 192 94
Nov. 1998 264 130
Dec. 1998 316 170
Jan. 1999 384 203
Feb. 1999 455 239
Mar. 1999 523 280
Apr. 1999 603 321
May 1999 674 369
(A)Have ordered Apligraf one or more times since launch
(B)Have re-ordered Apligraf one or more times since launch
Apligraf Commercial Units
Time Period Quarter Month
3Q98 548
4Q98 1070
1Q99 1585
April 1999 604
May 1999 552
-0- "While there was a slow down in unit sales in the week heading into the Memorial Day holiday, interest in Apligraf continued to grow as reflected by its broadening user base and the largest increase to date in sites re-ordering the product for the first time," said Alan Tuck, Chief Strategic Officer. "Several important events are planned by Novartis in June, further increasing Apligraf exposure. These include educational events at the American Diabetes Association The American Diabetes Association, or the ADA, is an American health organization providing diabetes research, information and advocacy. Founded in 1940, the American Diabetes Association conducts programs in all 50 states and the District of Columbia, reaching hundreds of meeting, at which the Deaconness Joslin Foot Center will be presenting data on Apligraf in diabetic foot ulcers." Like human skin, Apligraf is living, all-natural and bi-layered, with both an upper epidermal Epidermal Referring to the thin outermost layer of the skin, itself made up of several layers, that covers and protects the underlying dermis (skin). Mentioned in: Antiangiogenic Therapy, Histiocytosis X epidermal and a lower dermal dermal /der·mal/ (der´mal) pertaining to the dermis or to the skin. der·mal or der·mic adj. Of or relating to the skin or dermis. layer. It contains living human skin cells - epidermal keratinocytes Keratinocytes Cells found in the epidermis. The keratinocytes at the outer surface of the epidermis are dead and form a tough protective layer. The cells underneath divide to replenish the supply. and dermal fibroblasts Fibroblasts A type of cell found in connective tissue; produces collagen. Mentioned in: Skin Grafting . The keratinocytes are differentiated to form the strata of the human epidermis, including the outer stratum corneum. Unlike human skin, Apligraf does not contain structures such as blood vessels, hair follicles Hair follicles Tiny organs in the skin, each one of which grows a single hair. Mentioned in: Alopecia and sweat glands. Novartis Pharma AG has global Apligraf marketing rights. Organogenesis Inc. designs, develops and manufactures medical products containing living cells and/or natural connective tissue. The Company's product development focus includes living tissue replacements, cell-based organ assist devices and other tissue-engineered products. In addition to Apligraf, the pipeline includes VITRIX(TM) living soft tissue replacement, a bioartificial liver and a vascular graft. Statements in this press release which are not historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 and involve risks and uncertainties. There can be no assurance as to the rate of growth of Apligraf sales. Apligraf(R) is a registered trademark of Novartis. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion